Connect Biopharma (CNTB) Competitors $2.27 -0.11 (-4.62%) Closing price 04:00 PM EasternExtended Trading$2.23 -0.04 (-1.76%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. RGNX, ERAS, CMPX, AQST, CMPS, SNDL, MBX, TECX, SVRA, and GOSSShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include REGENXBIO (RGNX), Erasca (ERAS), Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), SNDL (SNDL), MBX Biosciences (MBX), Tectonic Therapeutic (TECX), Savara (SVRA), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors REGENXBIO Erasca Compass Therapeutics Aquestive Therapeutics COMPASS Pathways SNDL MBX Biosciences Tectonic Therapeutic Savara Gossamer Bio Connect Biopharma (NASDAQ:CNTB) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Do analysts rate CNTB or RGNX? Connect Biopharma presently has a consensus price target of $7.00, indicating a potential upside of 208.37%. REGENXBIO has a consensus price target of $31.63, indicating a potential upside of 247.91%. Given REGENXBIO's higher possible upside, analysts plainly believe REGENXBIO is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media refer more to CNTB or RGNX? In the previous week, Connect Biopharma had 4 more articles in the media than REGENXBIO. MarketBeat recorded 9 mentions for Connect Biopharma and 5 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.88 beat Connect Biopharma's score of 0.07 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CNTB or RGNX more profitable? Connect Biopharma has a net margin of 0.00% compared to REGENXBIO's net margin of -100.62%. Connect Biopharma's return on equity of 0.00% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A REGENXBIO -100.62%-53.29%-30.84% Which has more volatility and risk, CNTB or RGNX? Connect Biopharma has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Which has preferable valuation and earnings, CNTB or RGNX? Connect Biopharma has higher earnings, but lower revenue than REGENXBIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$26.03M4.85-$15.63MN/AN/AREGENXBIO$83.33M5.47-$227.10M-$3.11-2.92 Do institutionals and insiders have more ownership in CNTB or RGNX? 58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 12.8% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryConnect Biopharma beats REGENXBIO on 8 of the 15 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.24M$2.99B$5.57B$9.43BDividend YieldN/A2.44%4.05%3.99%P/E RatioN/A21.1128.0520.08Price / Sales4.85330.50428.2394.45Price / CashN/A41.9636.1958.45Price / Book1.368.198.605.83Net Income-$15.63M-$55.10M$3.24B$258.27M7 Day Performance40.12%7.71%4.63%3.98%1 Month Performance132.82%21.81%12.93%14.89%1 Year Performance71.97%6.57%35.40%19.29% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma2.6709 of 5 stars$2.27-4.6%$7.00+208.4%+88.9%$132.24M$26.03M0.00110News CoverageAnalyst UpgradeGap UpHigh Trading VolumeRGNXREGENXBIO4.1709 of 5 stars$8.47+3.8%$31.63+273.3%-32.9%$424.96M$83.33M-2.72370Analyst RevisionERASErasca2.1501 of 5 stars$1.51+0.3%$4.57+203.7%-46.5%$424.09MN/A-2.41120CMPXCompass Therapeutics2.2794 of 5 stars$3.08+2.5%$12.67+311.9%+207.0%$422.31M$850K-7.4520AQSTAquestive Therapeutics1.4144 of 5 stars$4.23+0.6%$10.14+140.1%+31.0%$419.67M$57.56M-7.16160Positive NewsCMPSCOMPASS Pathways2.0029 of 5 stars$4.45+3.4%$17.00+282.4%-40.5%$415.97MN/A-2.23120Upcoming EarningsGap UpHigh Trading VolumeSNDLSNDL1.3988 of 5 stars$1.58+2.3%$4.00+154.0%-27.8%$413.88M$671.81M-5.432,516MBXMBX Biosciences2.413 of 5 stars$12.22+4.0%$37.57+207.6%N/A$412.45MN/A0.0036TECXTectonic Therapeutic2.674 of 5 stars$22.00+0.4%$80.33+265.1%+33.5%$407.32MN/A-2.98120Positive NewsAnalyst ForecastSVRASavara1.8956 of 5 stars$2.30+1.5%$5.60+144.0%-47.8%$396.67MN/A-4.7820Positive NewsGOSSGossamer Bio3.5361 of 5 stars$1.75+2.6%$8.25+372.8%+62.3%$396.64M$114.70M-7.59180 Related Companies and Tools Related Companies RGNX Competitors ERAS Competitors CMPX Competitors AQST Competitors CMPS Competitors SNDL Competitors MBX Competitors TECX Competitors SVRA Competitors GOSS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts